Treatment priorities in oncology: Do we want to live longer or better?

Clinics

Volumn 69, Issue 8, 2014, Pages 509-514

  Marta, Guilherme Nader ^a   Del Nero, Luís G ^a   Marta, Gustavo Nader ^a,b   Mangabeira, Andrea ^c   Critchi, Gabriela ^c   Kovács, Maria J ^a   da Silva, João Luis Fernandes ^b   Saad, Everardo D ^c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL SÍRIO LIBANÊS   (Brazil)

^c Dendrix Research   (Brazil)

Author keywords

Oncology; Quality of Life; Survival

Indexed keywords

ADULT; AGED; BRAZIL; CROSS-SECTIONAL STUDY; DECISION MAKING; FEMALE; HEALTH CARE PERSONNEL; HUMAN; LONGEVITY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; PSYCHOLOGY; QUALITY OF LIFE; QUESTIONNAIRE; SURVIVAL; YOUNG ADULT;

ADULT; AGED; BRAZIL; CROSS-SECTIONAL STUDIES; DECISION MAKING; FEMALE; HEALTH PERSONNEL; HUMANS; LONGEVITY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; SURVIVAL; YOUNG ADULT;

EID: 84906214373     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2014(08)02     Document Type: Article

References (19)

1. Kris MG, Benowitz SI, Adams S, Diller L, Ganz P, Kahlenberg MS, et al. Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2010;28(36):5327-47, http://dx.doi.org/10.1200/JCO.2010.33.2742.
2. Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE, et al. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol. 2011;30(1):88-109.
3. Roth BJ, Krilov L, Adams S, Aghajanian CA, Bach P, Braiteh F, et al. Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol. 2013;31(1):131-61, http://dx.doi.org/10.1200/JCO.2012.47.1938.
4. Peppercorn JM, Smith TJ, Helft PR, Debono DJ, Berry SR, Wollins DS, et al. American society of clinical oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol. 2011;29(6):755-60, http://dx.doi.org/10.1200/JCO.2010.33.1744.
5. Johnson JR, Temple R. Food and Drug Administration requirements for approval of new anticancer drugs. Cancer Treat Rep. 1985;69(10):1155-9.
6. Sargent D. General and statistical hierarchy of appropriate biologic endpoints. Oncology (Williston Park). 2006;20(6 Suppl 5):5-9.
7. Smith I. Goals of treatment for patients with metastatic breast cancer. Semin Oncol. 2006;33(1 Suppl 2):S2-5, http://dx.doi.org/10.1053/j. seminoncol.2005.07.030.
8. Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist. 2008;13(Suppl 2):19-21, http://dx.doi.org/10.1634/theoncologist.13-S2-19.
9. Ocana A, Amir E, Vera F, Eisenhauer EA, Tannock IF. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J Clin Oncol. 2011;29(3):254-6, http:// dx.doi.org/10.1200/JCO.2010.32.0275.
10. Fleming TR, Rothmann MD, Lu HL. Issues in using progression-free survival when evaluating oncology products. J Clin Oncol. 2009; 27(17):2874-80, http://dx.doi.org/10.1200/JCO.2008.20.4107.
11. Matsuyama R, Reddy S, Smith TJ. Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol. 2006;24(21):3490-6, http://dx.doi.org/10.1200/ JCO.2005.03.6236.
12. Saad ED, Pinheiro CM, Masson AL, Borghesi G, Hoff PM, Prisco FE. Increasing output and low publication rate of Brazilian studies presented at the American Society of Clinical Oncology Annual Meetings. Clinics. 2008;63(3):293-6, http://dx.doi.org/10.1590/S1807-59322008000300001.
13. Slevin ML, Stubbs L, Plant HJ, Wilson P, Gregory WM, Armes PJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ. 1990;300(6737): 1458-60, http://dx.doi.org/10.1136/bmj.300.6737.1458.
14. Balmer CE, Thomas P, Osborne RJ. Who wants second-line, palliative chemotherapy? Psychooncology. 2001;10(5):410-8, http://dx.doi.org/10. 1002/pon.538.
15. Bremnes RM, Andersen K, Wist EA. Cancer patients, doctors and nurses vary in their willingness to undertake cancer chemotherapy. Eur J Cancer. 1995;31A(12):1955-9.
16. Hirose T, Horichi N, Ohmori T, Kusumoto S, Sugiyama T, Shirai T, et al. Patients preferences in chemotherapy for advanced non-small-cell lung cancer. Intern Med. 2005;44(2):107-13, http://dx.doi.org/10.2169/ internalmedicine.44.107.
17. McQuellon RP, Muss HB, Hoffman SL, Russell G, Craven B, Yellen SB. Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer. J Clin Oncol. 1995;13(4):858-68.
18. Crawford ED, Bennett CL, Stone NN, Knight SJ, DeAntoni E, Sharp L, et al. Comparison of perspectives on prostate cancer: analyses of survey data. Urology. 1997;50(3):366-72, http://dx.doi.org/10.1016/ S0090-4295(97)00254-9.
19. Weeks JC, Cook EF, O'Day SJ, Peterson LM, Wenger N, Reding D, et al. Relationship between cancer patients' predictions of prognosis and their treatment preferences. JAMA. 1998;279(21):1709-14, http://dx.doi.org/ 10.1001/jama.279.21.1709.